Widgerow Alan D, Ziegler Mary E, Garruto John A, Bell Michaela
All authors are with ALASTIN Skincare in Carlsbad, Califorinia. Drs. Widgerow and Ziegler are also with the Center for Tissue Engineering (CTE) at University of California Irvine in Irvine, California.
J Clin Aesthet Dermatol. 2022 Aug;15(8):E53-E60.
Following previous clinical trials, an antiaging product (Restorative Skin complex [RSC]; Alastin Skin Care Carlsbad, a Galderma company), was investigated for its effects on Klotho gene regulation, telomere length, and histological biopsy changes to provide a comprehensive picture of the mechanism and efficacy of its anti-aging effect.
Neonatal human fibroblasts were used for telomere length studies to examine the effect of the full RSC formulation and the amino acid components Tripeptide-1 and Hexapeptide-12 (TriHex™) on these cellular aging mechanisms. In addition, RNA sequencing was conducted using human keratinocytes specifically investigating Klotho and related genes. This was supplemented by a clinical study using biopsy samples.
TriHex™ significantly upregulated the Klotho gene and related FGF23, FGFR1 and FOXO3B anti-aging genes. Significant telomere shortening reduction over control was demonstrated with the RSC formulation at four weeks and with TriHex™ at six weeks for all percentiles tested. Previous clinical studies demonstrated that the use of the antiaging regimen for 12 weeks produced a statistically significant improvement in scores for all evaluated parameters. Restaining of previous biopsy blocks from the clinical trial revealed positive ECM changes, stimulation of collagen, fibrillin, CD44 and elastin.
The study was limited by a relatively small numbers of patients in the clinical trial and the non-competitive nature of the trial.
RSC anti-aging formulation and its TriHex™ components demonstrated significant reduction in telomere shortening, upregulation of Klotho and FOXO3 genes and biopsy validation of anti-aging efficacy. This new science supplements previous trials that demonstrated clinical efficacy of the formulation.
继先前的临床试验之后，对一种抗衰老产品（修复肌肤复合物[RSC]；Alastin Skin Care Carlsbad，高德美公司旗下品牌）进行研究，以考察其对klotho基因调控、端粒长度及组织活检变化的影响，从而全面了解其抗衰老作用的机制及功效。
使用新生儿人成纤维细胞进行端粒长度研究，以检验完整RSC配方以及氨基酸成分三肽-1和六肽-12（TriHex™）对这些细胞衰老机制的影响。此外，使用人角质形成细胞进行RNA测序，专门研究klotho及相关基因。并通过一项使用活检样本的临床研究加以补充。
TriHex™显著上调了klotho基因以及相关的成纤维细胞生长因子23（FGF23）、成纤维细胞生长因子受体1（FGFR1）和叉头框蛋白O3B（FOXO3B）抗衰老基因。对于所有测试百分位数，RSC配方在四周时以及TriHex™在六周时均显示出与对照组相比端粒缩短显著减少。先前的临床研究表明，使用该抗衰老方案12周后，所有评估参数的评分均有统计学上的显著改善。对先前临床试验中的活检组织块重新染色显示，细胞外基质有积极变化，胶原蛋白、原纤蛋白、CD44和弹性蛋白受到刺激。
该研究受限于临床试验中相对较少的患者数量以及试验的非竞争性性质。
RSC抗衰老配方及其TriHex™成分显示出端粒缩短显著减少、klotho和FOXO3基因上调以及抗衰老功效的活检验证。这一新的科学成果补充了先前证明该配方具有临床疗效的试验。
